Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A February 2024 study concluded that oral semaglutide may be most valuable as an add-on to the injectable form
Lofficier & Lofficier 2002, pp
Weight loss injections, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro)which is actually a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonisthave gained widespread attention for their effectiveness in managing obesity and type 2 diabetes
This paper helps close that gap by providing evidence-based data that can be applied from prior weight loss science, while paving the way for future research combining GLP-1 and supplement interventions. According to the papers disclosure of interest, all authors are employed by GNC Holdings
